




Monthly rate of metastatic disease mortality




Montly rate of recurrence in CDX2-positive patients







Hazard ratio for developing recurrence in CDX2-negative







Proportion of recurrences that are metastatic







Monthly rate of metastatic disease mortality



Monthly rate of recurrence in CDX2-positive patients



Hazard ratio for developing recurrence in CDX2-negative



Proportion of recurrences that are metastatic

Corr:
-0.290***

Corr:
-0.014

Corr:
0.041

Corr:
-0.489***

Corr:
-0.179***

Corr:
0.017